Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy

详细信息    查看全文

• 作者：Silvia Montoro-Garc&iacute ; a^a ; Diana Herná ; ndez-Romero^a ; Eva Jover^a ; Antonio Garc&iacute ; a-Honrubia^b ; Juan A. Vilchez^c ; Teresa Casas^c ; Pedro Mart&iacute ; nez^c ; Vicente Climent^b ; Luis Caballero^b ; Mariano Valdé ; s^a ; Francisco Mar&iacute ; n^a ; ^{fcomarino@hotmail.com}
• 关键词：GDF-15 ; growth differentiation factor-15 ; TGF-¦Â ; transforming growth factor ¦Â ; HCM ; hypertrophic cardiomyopathy ; MET ; metabolic equivalent ; NYHA ; New York Heart Association ; cMRI ; cardiac magnetic resonance imaging ; NT-proBNP ; amino-terminal pro-B-type
• 刊名：European Journal of Internal Medicine
• 出版年：2012
• 出版时间：March 2012
• 年：2012
• 卷：23
• 期：2
• 页码：169-174
• 全文大小：319 K

文摘

Background

The growth differentiation factor 15 (GDF-15) has been shown up-regulated in stress conditions and to have regulatory actions in myocyte hypertrophy. We hypothesized that GDF-15 could be related to disease severity and functional status in patients with hypertrophic cardiomyopathy (HCM).

Methods and results

We performed a study which includes 102 consecutive outpatient HCM subjects, 73 % males, aged 47.1 ¡À 14.6 years. A complete history and clinical examination was performed, including 12-lead electrocardiogram, echocardiography, symptom-limited treadmill exercise, 24-hour ECG-Holter monitoring, and magnetic resonance with Gadolinium. Several biomarkers, associated with myocardial remodeling and damage, were compared to GDF-15 levels. The assays were performed with commercial ELISAs or standardized methods when available. There was a significant association between GDF-15 levels and comorbidities, being higher in hypertension (p = 0.001), diabetes (p = 0.030), atrial fibrillation (p = 0.012), dyspnea (p = 0.020) and NYHA ?#xA0;II functional class (p = 0.037). GDF-15 levels were positively correlated with clinical variables (age, worse exercise capacity and mild renal dysfunction) and biomarkers of interstitial remodeling, such as metalloproteinase-2 (r: 0.40; p = 0.009), N-terminal pro-B-type natriuretic peptide (r: 0.28; p = 0.049), high-sensitivity troponin T (r: 0.30; p = 0.003) and von Willebrand factor (r: 0.33; p = 0.001). Multivariate analysis was assessed to estimate the involvement of these different factors in the GDF-15 levels, confirming the independent implication of severe dyspnea and functional status.

Conclusions

The present results show that higher levels of GDF-15 are associated to conditions of severe disease in HCM. Hence, GDF-15 is suggested as a novel marker related to the severity and could represent a further useful tool in monitoring functional capacity of HCM patients.